IDH1 and glioblastoma: LGG patients with IDH1 mutations will have a better prognosis and therapeutic response than those with wild-type IDH1. Mutations in the IDH1 gene are commonly present in more than 70% of LGGs and secondary glioblastomas [25], which is consistent with our data (404/520 = 77.7%) (Figure 2B and Figure 3A).